Study of Photopheresis in the Treatment of Erythrodermic MF and SS

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2020

Primary Completion Date

September 1, 2022

Study Completion Date

June 1, 2026

Conditions
Lymphoma, T-Cell, CutaneousMycosis Fungoides/Sezary Syndrome
Interventions
DRUG

Methoxsalen

"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"

DEVICE

THERAKOS CELLEX Photopheresis System

Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.

Trial Locations (1)

Unknown

UniversitaetsSpital Zurich - Division of Dermatology, Zurich

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK